someone explain satiety to me like I have not read a paper in years
Question in the title, detail here: someone explain satiety to me like I have not read a paper in years.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Would rather be corrected in public than confident in private.
best — the order this archive was captured in
The honest state of the evidence on this board, since somebody should write it down.
Published clinical data exists and is genuinely interesting, particularly in combination. Independent purity data from members is thin — a handful of results across the whole site, against hundreds for the older molecules. Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
What follows practically: buy small if you buy at all, test what you get and post the result, and treat confident rankings against established compounds as the extrapolation they are. The board gets better as the log fills, and right now the log is nearly empty.
satiety signalling rather than incretin signalling
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
Are you comparing against a GLP-1 monotherapy result?
Agreed, and the combination arms are where the interesting numbers actually live.
How many separate lots has anyone here tested?
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
phase 3 data will change most of what gets said here